Experiencing the Risks of Overutilizing Opioids Among Patients With Chronic Noncancer Pain in Ambulant Care

Not Applicable

• Conditions: R52.1; M54.9; Chronic intractable pain; Dorsalgia, unspecified

• Registration Number: DRKS00020358
• Lead Sponsor: Max-Planck-Institut für Bildungsforschung/Center for Adaptive Rationality

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Study Start: 2020-01-07
• Study Completion: 2021-04-15
• Last Update Posted: 19 August 2024

Recruitment & Eligibility

• Status: Complete
• Sex: All
• Target Recruitment: 1241

Inclusion Criteria

A. Study population for testing the comprehensibility of questionnaires and study materials (comprehension pilot) (N = 40):

A1. Patients with chronic (=3 month) noncancer pain: n = 20

A2. Family physicians licensed for narcotic prescriptions (BtM) and physicians specialized in special pain therapy: n = 10

A3. Pharmacists licensed for narcotic substances: n = 10

Data from this comprehension pilot is not evaluated in a confirmatory manner.

B. Study population for the RCT (N = 1.200):

B1. Family physicians licensed for narcotic prescriptions (BtM): n = 300

B2. Physicians specialized in Special pain management: n = 300

B3. Patients with chronic (=3 month) noncancer pain: n = 300

B4. Pharmacists licensed for narcotic substances: n = 300

All four study populations will be examined with an identical methodological design (pre-/post-intervention online survey).

Exclusion Criteria

Study population 1:
Family physicians NOT licensed for prescribing narcotic substances

Study population 2:
Physicians NOT specialized in Special pain management

Study population 3:
- Patients with tumor-related chronic pain
- Patients with chronic noncancer pain = 3 months

Study population 4:
Pharmacists NOT licensed for narcotic substances such as opioids

Study & Design

• Study Type: interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
(i) Objective risk perception; (ii) subjective risk perception; (iii) risk behavior (physicians' prescription behavior; patients' intake behavior; pharmacists counseling behavior)

Secondary Outcome Measures

Name	Time	Method
(i) differences in risk perception and behavior as a function of how a person learnt about the risks;<br>(ii) differences in risk perception and behavior as a function of an individual’s medical risk literacy; (iii) concordance between actual risk behavior reported at 9-months follow-up and intended change in risk behavior reported immediately after the intervention